Endeavour Vision announced today that it closed the Endeavour Medtech Growth II fund at $375 million in capital commitments.
Geneva, Switzerland-based Endeavour said in a news release that the fund is set up to support growth-stage medtech and digital health innovations. New and returning investors are supporting EMG II. The fund follows its original growth fund, which launched in 2016 with $275 million.
EMG II adds to Endeavour Vision’s two decades of healthcare investing that has, to date, invested over $500 million in 42 companies, of which 21 have exited through an acquisition or IPO.
The fund has already supported seven companies with investments totaling more than $100 million, with IntelyCare, CeQur, Rapid Micro Biosystems, Sophia Genetics, Nalu Medical, Lumeon and Relievant Medsystems receiving funding from EMG II.
“Governments, citizens and investors are now more aware than ever of our healthcare systems’ strategic importance and current limitations,” Endeavour Vision co-founder & managing partner Bernard Vogel said in the release. “This is accelerating the demand for pioneering solutions that can deliver sustainable healthcare. As such, EMG II LP’s timing could not be better. We want to thank the fund’s investors for their confidence in our team and strategy. In backing the bright future of this fast-growing, dynamic industry, our investors will also benefit from seeing the direct impact of their investments on people’s lives.”